Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals' stock has been influenced by analyst ratings, a share repurchase program, insider selling, stock performance, and earnings reports. Analyst ratings are generally positive, with a consensus "Buy" rating. The company announced a $200 million share repurchase plan. Over the last three months, company insiders have sold shares. The stock reached a 52-week low in September 2025. The company reported earnings per share of $0.28 for the quarter ending September 25th, 2025, with revenue of $53.11 million.

Demand for Catalyst Pharmaceuticals' products does not typically exhibit strong seasonality. Rare disease treatments address chronic and life-threatening conditions, leading to consistent demand driven by diagnosis rates, patient access, and regulatory approvals rather than seasonal fluctuations. The orphan drug market is characterized by steady growth due to increased investment, regulatory incentives, and rising rare disease diagnoses, further supporting the lack of significant seasonality for these specialized therapies.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its core business involves in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Major products include FIRDAPSE for Lambert-Eaton myasthenic syndrome (LEMS), AGAMREE for Duchenne muscular dystrophy (DMD), and FYCOMPA for treating seizures.

Catalyst Pharmaceuticals has a well-established presence in the United States, which is the cornerstone of its commercial strategy. The company is continuously evaluating strategic opportunities to expand its global footprint. FIRDAPSE is also offered in Canada and Japan through sub-licensees.

Catalyst Pharmaceuticals has maintained a positive brand reputation over the past year. The company was ranked 4th on Forbes' 2024 list of America's Most Successful Small-Cap Companies. The company also announced the settlement of FIRDAPSE patent litigation with Lupin Pharmaceuticals in August 2025.

Catalyst Pharmaceuticals is primarily owned by institutional shareholders, who hold 82.76% of the company. Insiders own 15.97%, and retail investors hold 1.27%. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and State Street Corp. Significant individual insider owners include Biomarin Pharmaceutical Inc., Patrick J. McEnany, and Hubert E. Md Huckel.